Status:
UNKNOWN
Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC
Lead Sponsor:
Fujian Cancer Hospital
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
18-70 years
Brief Summary
The purpose of this study was to evaluate its rationality in real-world data and provide clinical evidence for the refinement of nodal CTV delineation in nasopharyngeal carcinoma(NPC).
Detailed Description
Intensity-modulated radiation therapy (IMRT) has gradually replaced two-dimensional radiation therapy as it offers improved target conformity. Xerostomia is still the most common side effect of radiot...
Eligibility Criteria
Inclusion
- histologically confirmed NPC by biopsy (clearly recorded in the pathology report or medical history) ;
- no evidence of distant metastasis at initial diagnosis and receiving radical IMRT in our center
- the following conditions: ① level IB metastasis, ② involvement of the submandibular gland, ③ involvement of structures that drain to level Ib as the first echelon site ( the oral cavity, anterior half of nasal cavity involvement) ④ involvement of level II LNs with extracapsular extension（because the judgment of extracapsular invasion is greatly influenced by subjective factors, this study only include patients who had high grade ENE(G2/G3 as demonstrated in our previous study: Oral Oncol. 2019 Dec;99:104438.)⑤ level II nodal involvement with maximum nodal axial diameter greater than 2 cm.
- all patients who were treated at Lin Shaojun's attending group from June 2005 to December 2012.
- presence of complete baseline magnetic resonance imaging data of the nasopharyngeal skull base and neck and treated in our center at initial diagnosis .
Exclusion
- disease progression during IMRT;
- fail to obtain tumor efficacy evaluation information in the medical records of the research center;
- previous malignancy or other concomitant malignant disease;
- receiving blind treatment in clinical research.
Key Trial Info
Start Date :
May 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04745741
Start Date
May 1 2021
End Date
June 1 2021
Last Update
April 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of radiation oncology, Fujian cancer hospital
Fuzhou, Fujian, China, 350014